#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13820	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2443	696.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1901	1901	T	885	T,G,C	882,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13820	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2443	696.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1635	1635	C	822	C	822	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23066	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4085	704.0	0	.	n	.	0	T695C	SNP	695	695	T	1315	1315	C	829	C,G,A	827,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23066	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4085	704.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2591	2591	C	798	C,A,G	796,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23066	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4085	704.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3217	3217	T	800	T,G,A	797,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23066	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4085	704.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2665	2665	A	686	A,C	685,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2042	folP	855	855	100.0	folP.l15.c4.ctg.1	1990	127.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1224	1226	AGC	215;213;215	A;G;C	215;213;215	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4636	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3949	146.4	1	SNP	p	S91F	0	.	.	271	273	TCC	824	826	TCC	188;188;190	T;C;C	188;188;190	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4636	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3949	146.4	1	SNP	p	D95G	0	.	.	283	285	GAC	836	838	GAC	193;193;193	G;A;C	193;193;193	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4636	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3949	146.4	1	SNP	p	D95N	0	.	.	283	285	GAC	836	838	GAC	193;193;193	G;A;C	193;193;193	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1854	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1670	138.2	1	SNP	p	G45D	0	.	.	133	135	GGC	648	650	GGC	237;240;237	G;G;C	237;240;237	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	982	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1317	92.5	0	.	n	.	0	A197.	DEL	197	197	A	684	684	A	216	A	216	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3447	161.6	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1886	1888	GCA	223;224;223	G;C;A	222;223;222	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3447	161.6	1	SNP	p	D86N	0	.	.	256	258	GAC	839	841	GAC	200;200;201	G,T;A,C;C,T,G	199,1;198,2;199,1,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3447	161.6	1	SNP	p	S87I	0	.	.	259	261	AGT	842	844	AGT	195;196;198	A;G,T;T	195;195,1;198	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3447	161.6	1	SNP	p	S87W	0	.	.	259	261	AGT	842	844	AGT	195;196;198	A;G,T;T	195;195,1;198	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3447	161.6	1	SNP	p	S87R	0	.	.	259	261	AGT	842	844	AGT	195;196;198	A;G,T;T	195;195,1;198	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4464	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3447	161.6	1	SNP	p	S88P	0	.	.	262	264	TCC	845	847	TCC	199;201;203	T;C;C,T,A	199;201;200,1,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4128	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2999	171.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1715	1717	GGC	234;231;232	G,C;G,A;C	233,1;230,1;232	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1525	1527	GCA	206;207;205	G,T;C,A;A	205,1;206,1;205	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1528	1530	ATC	206;204;205	A,C;T;C,A	205,1;204;204,1	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1540	1542	GTG	206;207;209	G;T,G,A;G,T	206;204,2,1;208,1	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1540	1542	GTG	206;207;209	G;T,G,A;G,T	206;204,2,1;208,1	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2044	2046	ACC	220;223;223	A;C,G;C	220;222,1;223	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2098	2100	GCG	213;214;215	G;C,G,A;G	213;212,1,1;215	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2098	2100	GCG	213;214;215	G;C,G,A;G	213;212,1,1;215	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2221	2223	GGC	217;218;218	G;G,A,T;C,A,G	217;216,1,1;216,1,1	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2230	2232	GGC	220;216;218	G;G;C	220;216;218	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3796	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2959	160.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2248	2250	CCG	220;223;222	C,G;C;G,C	218,2;223;221,1	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	5190	ponA	2397	2397	99.87	ponA.l15.c4.ctg.1	3587	180.3	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1727	1729	ACG	210;208;203	A,G,C;C,A;G	208,1,1;207,1;203	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2224	porA	1146	1146	99.39	porA.l15.c4.ctg.1	2232	124.0	0	.	p	.	0	S22G	NONSYN	64	66	AGC	617	619	GGC	168;171;170	G;G;C,G	168;171;169,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2224	porA	1146	1146	99.39	porA.l15.c4.ctg.1	2232	124.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	799	799	C	171	C	171	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	312	porB1a	984	162	93.21	porB1a.l15.c17.ctg.2	162	60.2	0	.	p	.	0	V258L	NONSYN	772	774	GTA	21	23	TTA	32;35;38	T;T;A	32;35;38	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	312	porB1a	984	162	93.21	porB1a.l15.c17.ctg.2	162	60.2	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	66	68	CAT	78;78;78	C;A;T	78;78;78	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	312	porB1a	984	162	93.21	porB1a.l15.c17.ctg.2	162	60.2	0	.	p	.	0	D274S	NONSYN	820	822	GAT	69	71	AGT	78;78;78	A;G;T	78;78;78	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	312	porB1a	984	162	93.21	porB1a.l15.c17.ctg.2	162	60.2	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	78	80	TAC	78;78;78	T;A;C	78;78;78	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	312	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	595	21.8	0	.	p	.	0	M18T	NONSYN	52	54	ATG	546	548	ACG	53;50;50	A;C;G	53;50;50	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	312	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	595	21.8	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	588	590	CAA	15;11;7	C;A;A	15;11;7	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3184	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2130	186.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	730	732	GAA	280;281;279	G;A,C;A	280;280,1;279	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3184	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2130	186.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1018	1020	GAT	272;272;272	G,C;A,C;T	271,1;271,1;272	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3184	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2130	186.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1141	1143	TCA	253;255;256	T,G;C;A	252,1;254;256	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3184	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2130	186.2	0	.	p	.	0	D212N	NONSYN	634	636	GAT	1252	1254	AAT	271;270;269	A;A,T;T,G	271;269,1;268,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3184	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2130	186.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1270	1272	GTC	264;262;258	G,T,A;T,G;C	261,2,1;260,2;258	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3184	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2130	186.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1600	1602	GCA	248;248;247	G;C;A,G	248;248;246,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3184	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2130	186.2	1	SNP	p	G120K	1	.	.	358	360	AAG	976	978	AAG	277;278;281	A,C;A;G	276,1;278;281	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3184	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2130	186.2	1	SNP	p	A121D	1	.	.	361	363	GAC	979	981	GAC	281;282;280	G;A,C;C	281;281,1;280	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3184	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2130	186.2	1	SNP	p	D121N	0	.	.	361	363	GAC	979	981	GAC	281;282;280	G;A,C;C	281;281,1;280	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10222	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5199	244.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2149	2151	AAT	271;268;268	A;A,C;T,G	271;267,1;267,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1438	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1450	123.4	1	SNP	p	V57M	1	.	.	169	171	ATG	748	750	ATG	246;246;246	A;T;G	246;246;246	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
